Lipoprotein(a) in patients initiating antiretroviral therapy

HIV Medicine

Volumn 9, Issue 6, 2008, Pages 415-420

  Mauss, Stefan ^a   Berger, F ^a   Schmutz, G ^a   Henke, J ^a   Richter, W O ^b  

^a Center for HIV and Hepatogastroenterology   (Germany)

^b Institute for Lipid Metabolism   (Germany)

Author keywords

Antiretrovirals; Dyslipidaemia; Lipoprotein(a)

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ZIDOVUDINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; VIRAL LOAD; YOUNG ADULT;

EID: 47649116579     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00574.x     Document Type: Article

References (22)

1. DAD Study Group, Friis-Møller N, Reiss P et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
2. Holmberg SD, Moorman AC, Williamson JM et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747-1748.
3. Bergersen BM. Cardiovascular risk in patients with HIV infection: Impact of antiretroviral therapy. Drugs 2006; 66: 1971-1987.
4. Riddler SA, Li X, Chu H et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med 2007; 8: 280-287.
5. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-1085.
6. Cantin B, Després JP, Lamarche B et al. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol 2002; 89: 662-666.
7. Kronenberg F, Kronenberg MF, Kiechl S et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the Bruneck Study. Circulation 1999; 100: 1154-1160.
8. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37: 434-439.
9. Berglund L, Ramakrishnan R. Lipoprotein(a): An elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004; 24: 2219-2226.
10. Kostner KM, Kostner GM. Therapy of hyper-Lp(a). Handb Exp Pharmacol 2005; 170: 519-536.
11. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the national heart, lung, and blood institute workshop on lipoprotein(a) and cardiovascular disease: Recent advances and future directions. Clin Chem 2003; 49: 1785-1796.
12. Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100: 700-705.
13. Glader CA, Birgander LS, Stenlund H, Dahlén GH. Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med 2002; 252: 27-35.
14. Stubbs P, Seed M, Lane D, Collinson P, Kendall F, Noble M. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J 1998; 19: 1355-1364.
15. Shai I, Rimm EB, Hankinson SE et al. Lipoprotein(a) and coronary heart disease among women: Beyond a cholesterol carrier? Eur Heart J 2005; 26: 1633-1639.
16. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-1184.
17. Tsimikas S, Brilakis ES, Miller ER et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353: 46-57.
18. Ariyo AA, Thach C, Tracy R. Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003; 349: 2108-2115.
19. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006; 296: 1363-1370.
20. Voudris KA, Attilakos A, Katsarou E et al. Early and persistent increase in serum lipoprotein(a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy Res 2006; 70, 211-217.
21. Sonmez FM, Demir E, Orem A et al. Effect of antiepileptic drugs on plasma lipids, lipoprotein (a) and liver enzymes. J Child Neurol 2006; 21: 70-74.
22. Riddler SA, Smit E, Cole SR et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289: 2978-2982.